

# Rolf A Brekken

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8475823/publications.pdf>

Version: 2024-02-01

238  
papers

19,557  
citations

10986  
71  
h-index

13379  
130  
g-index

254  
all docs

254  
docs citations

254  
times ranked

28166  
citing authors

#	ARTICLE	IF	CITATIONS
1	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. <i>Nature Cell Biology</i> , 2000, 2, 737-744.	10.3	2,487
2	Hypoxia-Inducible Factor 1 $\alpha$ Induces Fibrosis and Insulin Resistance in White Adipose Tissue. <i>Molecular and Cellular Biology</i> , 2009, 29, 4467-4483.	2.3	720
3	Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer. <i>Cell Death and Differentiation</i> , 2016, 23, 962-978.	11.2	506
4	SPARC, a matricellular protein: at the crossroads of cellâ€matrix communication. <i>Matrix Biology</i> , 2001, 19, 815-827.	3.6	491
5	Pancreatic cancer stroma: an update on therapeutic targeting strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 487-505.	17.8	458
6	Role of VEGF-A in Vascularization of Pancreatic Islets. <i>Current Biology</i> , 2003, 13, 1070-1074.	3.9	351
7	Dichotomous effects of VEGF-A on adipose tissue dysfunction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5874-5879.	7.1	337
8	Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. <i>Nature Medicine</i> , 2009, 15, 1023-1030.	30.7	328
9	Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. <i>Oncogene</i> , 2002, 21, 7011-7026.	5.9	305
10	SPARC, a matricellular protein: at the crossroads of cellâ€matrix. <i>Matrix Biology</i> , 2000, 19, 569-580.	3.6	304
11	27-Hydroxycholesterol Promotes Cell-Autonomous, ER-Positive Breast Cancer Growth. <i>Cell Reports</i> , 2013, 5, 637-645.	6.4	289
12	Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature. <i>Clinical Cancer Research</i> , 2007, 13, 323-330.	7.0	256
13	Angiogenic Role of LYVE-1â€Positive Macrophages in Adipose Tissue. <i>Circulation Research</i> , 2007, 100, e47-57.	4.5	253
14	A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. <i>Nature Communications</i> , 2013, 4, 2035.	12.8	252
15	A Peptoid â€Antibody Surrogateâ€That Antagonizes VEGF Receptor 2 Activity. <i>Journal of the American Chemical Society</i> , 2008, 130, 5744-5752.	13.7	220
16	Non-nuclear estrogen receptor $\beta$ signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. <i>Journal of Clinical Investigation</i> , 2010, 120, 2319-2330.	8.2	217
17	Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e7464.	2.5	205
18	Exploration of Nanoparticle-Mediated Photothermal Effect of TMB-H <sub>2</sub> O <sub>2</sub> Colorimetric System and Its Application in a Visual Quantitative Photothermal Immunoassay. <i>Analytical Chemistry</i> , 2018, 90, 5930-5937.	6.5	201

#	ARTICLE	IF	CITATIONS
19	Vascular Endothelial Growth Factor Promotes Fibrosis Resolution and Repair in Mice. Gastroenterology, 2014, 146, 1339-1350.e1.	1.3	196
20	TBK1 Directly Engages Akt/PKB Survival Signaling to Support Oncogenic Transformation. Molecular Cell, 2011, 41, 458-470.	9.7	187
21	Vascular Endothelial Growth Factor Receptor 2 Mediates Macrophage Infiltration into Orthotopic Pancreatic Tumors in Mice. Cancer Research, 2008, 68, 4340-4346.	0.9	175
22	Macrophage-Derived SPARC Bridges Tumor Cell-Extracellular Matrix Interactions toward Metastasis. Cancer Research, 2008, 68, 9050-9059.	0.9	174
23	Molecular Consequences of Silencing Mutant K- <i>ras</i> in Pancreatic Cancer Cells: Justification for K- <i>ras</i> -Directed Therapy. Molecular Cancer Research, 2005, 3, 413-423.	3.4	173
24	Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. Journal of Clinical Investigation, 2003, 111, 487-495.	8.2	170
25	Targeting interleukin-6 as a strategy to overcome stroma-induced resistance to chemotherapy in gastric cancer. Molecular Cancer, 2019, 18, 68.	19.2	169
26	Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution. JCI Insight, 2019, 4, .	5.0	169
27	Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer. PLoS ONE, 2009, 4, e7669.	2.5	168
28	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. Journal of Clinical Investigation, 2013, 123, 1732-1740.	8.2	166
29	Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Molecular Cancer Therapeutics, 2009, 8, 1761-1771.	4.1	165
30	A transistor-like pH nanoprobe for tumour detection and image-guided surgery. Nature Biomedical Engineering, 2017, 1, .	22.5	163
31	Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell, 2022, 40, 656-673.e7.	16.8	155
32	Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer. Cell, 2013, 155, 552-566.	28.9	151
33	SPARC: a matricellular regulator of tumorigenesis. Journal of Cell Communication and Signaling, 2009, 3, 255-273.	3.4	147
34	Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research, 2003, 63, 5376-80.	0.9	146
35	The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs, 2010, 2, 165-175.	5.2	144
36	Enhanced Growth of Pancreatic Tumors in <i>SPARC-Null</i> Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis. Molecular Cancer Research, 2004, 2, 215-224.	3.4	134

#	ARTICLE	IF	CITATIONS
37	Fibulin-5, an integrin-binding matricellular protein: its function in development and disease. <i>Journal of Cell Communication and Signaling</i> , 2009, 3, 337-347.	3.4	131
38	Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. <i>Cancer Research</i> , 2015, 75, 3699-3705.	0.9	127
39	Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 246-255.	0.9	127
40	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. <i>Endocrine-Related Cancer</i> , 2006, 13, 905-919.	3.1	125
41	Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend <i>C. elegans</i> lifespan. <i>Nature Communications</i> , 2017, 8, 2270.	12.8	121
42	Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor- $\beta$ receptor type I inhibitor. <i>Oncotarget</i> , 2018, 9, 6659-6677.	1.8	112
43	Age-Related Changes in Vascular Endothelial Growth Factor Dependency and Angiopoietin-1-Induced Plasticity of Adult Blood Vessels. <i>Circulation Research</i> , 2004, 94, 984-992.	4.5	111
44	Ultrastructural Localization of the Vascular Permeability Factor/Vascular Endothelial Growth Factor (VPF/VEGF) Receptor-2 (FLK-1, KDR) in Normal Mouse Kidney and in the Hyperpermeable Vessels Induced by VPF/VEGF-expressing Tumors and Adenoviral Vectors. <i>Journal of Histochemistry and Cytochemistry</i> , 2000, 48, 545-555.	2.5	106
45	RHOA-FAK Is a Required Signaling Axis for the Maintenance of KRAS-Driven Lung Adenocarcinomas. <i>Cancer Discovery</i> , 2013, 3, 444-457.	9.4	104
46	SPARC-like 1 Regulates the Terminal Phase of Radial Glia-Guided Migration in the Cerebral Cortex. <i>Neuron</i> , 2004, 41, 57-69.	8.1	103
47	Detection of phosphatidylserine-positive exosomes for the diagnosis of early-stage malignancies. <i>British Journal of Cancer</i> , 2017, 117, 545-552.	6.4	103
48	Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 57-72.	2.4	101
49	Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer. <i>Cancer Research</i> , 2010, 70, 2852-2861.	0.9	99
50	Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of $\beta$ -Lapachone for Pancreatic Cancer Therapy. <i>Clinical Cancer Research</i> , 2011, 17, 275-285.	7.0	96
51	SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. <i>Journal of Cellular Biochemistry</i> , 2004, 91, 915-925.	2.6	94
52	Enhanced Heme Function and Mitochondrial Respiration Promote the Progression of Lung Cancer Cells. <i>PLoS ONE</i> , 2013, 8, e63402.	2.5	92
53	BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 992-1001.	4.1	90
54	Targeting vascular endothelium with avidin microbubbles. <i>Ultrasound in Medicine and Biology</i> , 2005, 31, 1279-1283.	1.5	89

#	ARTICLE	IF	CITATIONS
55	Matrix control of pancreatic cancer: New insights into fibronectin signaling. <i>Cancer Letters</i> , 2016, 381, 252-258.	7.2	89
56	Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. <i>International Journal of Cancer</i> , 2007, 121, 2181-2191.	5.1	88
57	Collagen Signaling Enhances Tumor Progression after Anti-VEGF Therapy in a Murine Model of Pancreatic Ductal Adenocarcinoma. <i>Cancer Research</i> , 2014, 74, 1032-1044.	0.9	88
58	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2473-2485.	4.1	86
59	Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. <i>Journal of Clinical Investigation</i> , 2006, 116, 422-429.	8.2	84
60	TGF- $\beta$ 2 and $\alpha$ 6 $\beta$ 1 Integrin Act in a Common Pathway to Suppress Pancreatic Cancer Progression. <i>Cancer Research</i> , 2012, 72, 4840-4845.	0.9	82
61	CXCL1 promotes tumor growth through VEGF pathway activation and is associated with inferior survival in gastric cancer. <i>Cancer Letters</i> , 2015, 359, 335-343.	7.2	82
62	The regulatory function of SPARC in vascular biology. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 3165-3173.	5.4	81
63	Sitravatinib potentiates immune checkpoint blockade in refractory cancer models. <i>JCI Insight</i> , 2018, 3, .	5.0	81
64	SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. <i>Nature Communications</i> , 2017, 8, 14098.	12.8	80
65	Phosphorylation of Akt and ERK1/2 Is Required for VEGF-A/VEGFR2-Induced Proliferation and Migration of Lymphatic Endothelium. <i>PLoS ONE</i> , 2011, 6, e28947.	2.5	79
66	A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis. <i>Oncogene</i> , 2017, 36, 5122-5133.	5.9	79
67	LKB1 loss promotes endometrial cancer progression via CCL2-dependent macrophage recruitment. <i>Journal of Clinical Investigation</i> , 2015, 125, 4063-4076.	8.2	79
68	Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy. <i>Journal of Clinical Investigation</i> , 2014, 124, 824-834.	8.2	78
69	Hypoxia Studies with Pimonidazole in vivo. <i>Bio-protocol</i> , 2014, 4, .	0.4	77
70	NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by $\alpha$ -lapachone. <i>Cell Death and Disease</i> , 2015, 6, e1599-e1599.	6.3	76
71	Progesterin-Dependent Progression of Human Breast Tumor Xenografts: A Novel Model for Evaluating Antitumor Therapeutics. <i>Cancer Research</i> , 2007, 67, 9929-9936.	0.9	75
72	Effect of Rapamycin Alone and in Combination with Antiangiogenesis Therapy in an Orthotopic Model of Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6993-7000.	7.0	74

#	ARTICLE	IF	CITATIONS
73	Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer. <i>Journal of the American College of Surgeons</i> , 2005, 200, 371-377.	0.5	74
74	The angiogenic ?vascular endothelial growth factor/flk-1 (KDR) receptor? pathway in patients with endometrial carcinoma. <i>Cancer</i> , 2001, 92, 2569-2577.	4.1	73
75	K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways. <i>Molecular Cancer Research</i> , 2009, 7, 799-808.	3.4	72
76	Semaphorin 3B Inhibits the Phosphatidylinositol 3-Kinase/Akt Pathway through Neuropilin-1 in Lung and Breast Cancer Cells. <i>Cancer Research</i> , 2008, 68, 8295-8303.	0.9	71
77	Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment. <i>Cancers</i> , 2020, 12, 2652.	3.7	71
78	Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice. <i>International Journal of Cancer</i> , 2006, 118, 2639-2643.	5.1	70
79	Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGF $\beta$ 2 Activation. <i>PLoS ONE</i> , 2012, 7, e31384.	2.5	69
80	Loss of SPARC in bladder cancer enhances carcinogenesis and progression. <i>Journal of Clinical Investigation</i> , 2013, 123, 751-66.	8.2	69
81	Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. <i>Molecular Cancer Research</i> , 2004, 2, 215-24.	3.4	68
82	SPARC regulates collagen interaction with cardiac fibroblast cell surfaces. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H841-H847.	3.2	66
83	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. <i>Journal of Thoracic Oncology</i> , 2020, 15, 973-999.	1.1	66
84	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF $\beta$ 1 activity. <i>Journal of Cell Biology</i> , 2011, 193, 1305-1319.	5.2	64
85	Recruitment and retention: factors that affect pericyte migration. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 299-309.	5.4	64
86	Compromised Production of Extracellular Matrix in Mice Lacking Secreted Protein, Acidic and Rich in Cysteine (SPARC) Leads to a Reduced Foreign Body Reaction to Implanted Biomaterials. <i>American Journal of Pathology</i> , 2003, 162, 627-635.	3.8	63
87	PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1190-1201.	4.1	63
88	Human pancreatic cancer cell exosomes, but not human normal cell exosomes, act as an initiator in cell transformation. <i>ELife</i> , 2019, 8, .	6.0	63
89	The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis. <i>Cancers</i> , 2021, 13, 6206.	3.7	63
90	Forced Expression of MMP9 Rescues the Loss of Angiogenesis and Abrogates Metastasis of Pancreatic Tumors Triggered by the Absence of Host SPARC. <i>Experimental Biology and Medicine</i> , 2008, 233, 860-873.	2.4	62

#	ARTICLE	IF	CITATIONS
91	SPARC Promotes Cathepsin B-Mediated Melanoma Invasiveness through a Collagen I/ $\alpha 2\beta 1$ Integrin Axis. <i>Journal of Investigative Dermatology</i> , 2011, 131, 2438-2447.	0.7	61
92	Vascular Endothelial Growth Factor Receptor-2 Promotes the Development of the Lymphatic Vasculature. <i>PLoS ONE</i> , 2013, 8, e74686.	2.5	61
93	SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. <i>Molecular Cancer</i> , 2014, 13, 237.	19.2	60
94	DDR1-induced neutrophil extracellular traps drive pancreatic cancer metastasis. <i>JCI Insight</i> , 2021, 6, .	5.0	60
95	Malignant Progression and Blockade of Angiogenesis in a Murine Transgenic Model of Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 9435-9442.	0.9	58
96	The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. <i>BMC Cancer</i> , 2008, 8, 352.	2.6	58
97	P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer. <i>Cell Reports</i> , 2016, 14, 2193-2208.	6.4	58
98	Role of SPARC in Bone Remodeling and Cancer-Related Bone Metastasis. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 17-26.	2.6	57
99	Skeletal Colonization by Breast Cancer Cells Is Stimulated by an Osteoblast and $\beta 2$ AR-Dependent Neo-Angiogenic Switch. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 1442-1454.	2.8	57
100	Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. <i>Wound Repair and Regeneration</i> , 2001, 9, 522-530.	3.0	56
101	Loss of fibulin-5 binding to $\beta 1$ integrins inhibits tumor growth by increasing the level of ROS. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 333-342.	2.4	56
102	Neutralizing Murine TGF $\beta$ 2 Promotes a Differentiated Tumor Cell Phenotype and Inhibits Pancreatic Cancer Metastasis. <i>Cancer Research</i> , 2014, 74, 4996-5007.	0.9	56
103	Targeting $\text{TGF}\beta 2$ mutant tumors exposes vulnerabilities to stromal $\text{TGF}\beta 2$ blockade in pancreatic cancer. <i>EMBO Molecular Medicine</i> , 2019, 11, e10515.	6.9	56
104	Expression and Characterization of Murine Hevin (SC1), a Member of the SPARC Family of Matricellular Proteins. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 735-748.	2.5	55
105	SMAC Mimetic (JP1201) Sensitizes Non-Small Cell Lung Cancers to Multiple Chemotherapy Agents in an IAP-Dependent but TNF-Independent Manner. <i>Cancer Research</i> , 2011, 71, 7640-7648.	0.9	55
106	Vascular channels formed by subpopulations of PECAM1+ melanoma cells. <i>Nature Communications</i> , 2014, 5, 5200.	12.8	55
107	From top to bottom: midkine and pleiotrophin as emerging players in immune regulation. <i>Journal of Leukocyte Biology</i> , 2017, 102, 277-286.	3.3	55
108	The matricellular protein SPARC is expressed in human trabecular meshwork. <i>Experimental Eye Research</i> , 2003, 77, 601-607.	2.6	54



#	ARTICLE	IF	CITATIONS
109	Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 5031-5042.	7.0	54
110	Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B. <i>Nature Chemical Biology</i> , 2015, 11, 401-408.	8.0	54
111	Strategies for vascular targeting in tumors. <i>International Journal of Cancer</i> , 2002, 100, 123-130.	5.1	53
112	Incorporation of Bone Marrow-derived Flk-1-expressing CD34+ Cells in the Endothelium of Tumor Vessels in the Mouse Brain. <i>Neurosurgery</i> , 2006, 59, 374-382.	1.1	53
113	Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5911-5916.	6.4	51
114	Actions of the protein kinase WNK1 on endothelial cells are differentially mediated by its substrate kinases OSR1 and SPAK. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 15999-16004.	7.1	50
115	Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. <i>Cell Death and Differentiation</i> , 2019, 26, 382-393.	11.2	49
116	Rgs16 and Rgs8 in embryonic endocrine pancreas and mouse models of diabetes. <i>DMM Disease Models and Mechanisms</i> , 2010, 3, 567-580.	2.4	48
117	MRI Detection of VEGFR2 <i>in Vivo</i> Using a Low Molecular Weight Peptoid <sup>8</sup> -Dendron for Targeting. <i>Journal of the American Chemical Society</i> , 2010, 132, 12829-12831.	13.7	48
118	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. <i>Cancer Letters</i> , 2015, 358, 59-66.	7.2	48
119	Discoidin domain receptor 1 activity drives an aggressive phenotype in gastric carcinoma. <i>BMC Cancer</i> , 2017, 17, 87.	2.6	48
120	Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25880-25890.	7.1	47
121	The effects of aging on tumor growth and angiogenesis are tumor-cell dependent. <i>International Journal of Cancer</i> , 2007, 120, 753-760.	5.1	44
122	2-Amino-2,3-dihydro-1 <i>H</i> -indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and <i>In Vivo</i> Antipancreatic Cancer Efficacy. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7431-7444.	6.4	43
123	The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity. <i>Science Translational Medicine</i> , 2016, 8, 365ra159.	12.4	42
124	Functional Analysis of the Matricellular Protein SPARC with Novel Monoclonal Antibodies. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 723-733.	2.5	40
125	Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance. <i>Neoplasia</i> , 2018, 20, 826-837.	5.3	40
126	Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. <i>Experimental Biology and Medicine</i> , 2010, 235, 3-9.	2.4	39



#	ARTICLE	IF	CITATIONS
127	Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Immunology</i> , 2019, 202, 292-299.	0.8	39
128	Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. <i>Oncotarget</i> , 2014, 5, 9811-9822.	1.8	39
129	r84, a Novel Therapeutic Antibody against Mouse and Human VEGF with Potent Anti-Tumor Activity and Limited Toxicity Induction. <i>PLoS ONE</i> , 2010, 5, e12031.	2.5	38
130	Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU tumour suppressor. <i>Nature Cell Biology</i> , 2017, 19, 1226-1236.	10.3	38
131	Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma. <i>Molecular Cancer Research</i> , 2018, 16, 1590-1600.	3.4	38
132	The Next Wave of Stroma-Targeting Therapy in Pancreatic Cancer. <i>Cancer Research</i> , 2019, 79, 328-330.	0.9	38
133	Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. <i>Experimental Biology and Medicine</i> , 2010, 235, 263-270.	2.4	37
134	Lack of "immunological fitness" during fasting in metabolically challenged animals. <i>Journal of Lipid Research</i> , 2012, 53, 1254-1267.	4.2	37
135	GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. <i>BMC Cancer</i> , 2010, 10, 397.	2.6	36
136	Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1. <i>Oncotarget</i> , 2016, 7, 30678-30690.	1.8	36
137	Inhibition of VEGFR-2 Reverses Type 1 Diabetes in NOD Mice by Abrogating Insulitis and Restoring Islet Function. <i>Diabetes</i> , 2013, 62, 2870-2878.	0.6	35
138	Hypoxia and Transforming Growth Factor $\beta^2$ Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer. <i>Journal of Biological Chemistry</i> , 2016, 291, 22244-22252.	3.4	35
139	MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 542-561.	9.4	35
140	Stromal Platelet-Derived Growth Factor Receptor $\beta$ (PDGFR $\beta$ ) Provides a Therapeutic Target Independent of Tumor Cell PDGFR $\beta$ Expression in Lung Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2473-2482.	4.1	34
141	VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells. <i>Molecular Therapy</i> , 2013, 21, 1014-1023.	8.2	34
142	Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 1-14.	5.8	34
143	The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5892-5894.	2.2	33
144	Accumulation of Pro-Cancer Cytokines in the Plasma Fraction of Stored Packed Red Cells. <i>Journal of Gastrointestinal Surgery</i> , 2012, 16, 460-468.	1.7	33

#	ARTICLE	IF	CITATIONS
145	Fibulin-5 Blocks Microenvironmental ROS in Pancreatic Cancer. <i>Cancer Research</i> , 2015, 75, 5058-5069.	0.9	33
146	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1357-1362.	1.1	32
147	Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 327-332.	2.8	31
148	Assessment of TANK-binding kinase 1 as a therapeutic target in cancer. <i>Journal of Cell Communication and Signaling</i> , 2018, 12, 83-90.	3.4	31
149	Getting a grip on adhesion: Cadherin switching and collagen signaling. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2019, 1866, 118472.	4.1	31
150	Expression of Soluble VEGF Receptor 2 and Characterization of Its Binding by Surface Plasmon Resonance. <i>Biochemical and Biophysical Research Communications</i> , 1998, 252, 643-648.	2.1	29
151	SPARC-thrombospondin-2-double-null Mice Exhibit Enhanced Cutaneous Wound Healing and Increased Fibrovascular Invasion of Subcutaneous Polyvinyl Alcohol Sponges. <i>Journal of Histochemistry and Cytochemistry</i> , 2005, 53, 571-581.	2.5	29
152	Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in human cultures established from mouse xenografts. <i>Cancer Biology and Therapy</i> , 2011, 12, 617-628.	3.4	29
153	SPARC is a key mediator of TGF $\beta$ -induced renal cancer metastasis. <i>Journal of Cellular Physiology</i> , 2021, 236, 1926-1938.	4.1	29
154	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells. <i>Cell Reports Medicine</i> , 2022, 3, 100554.	6.5	29
155	Selective Blockade of Vascular Endothelial Growth Factor Receptor 2 With an Antibody Against Tumor-Derived Vascular Endothelial Growth Factor Controls the Growth of Human Pancreatic Adenocarcinoma Xenografts. <i>Annals of Surgical Oncology</i> , 2006, 13, 1145-1155.	1.5	28
156	Inhibition of Multiple Pathogenic Pathways by Histone Deacetylase Inhibitor SAHA in a Corneal Alkali-Burn Injury Model. <i>Molecular Pharmaceutics</i> , 2013, 10, 307-318.	4.6	28
157	Unbiased Selection of Peptide-Peptoid Hybrids Specific for Lung Cancer Compared to Normal Lung Epithelial Cells. <i>ACS Chemical Biology</i> , 2015, 10, 2891-2899.	3.4	28
158	Direct and indirect regulation of the tumor immune microenvironment by VEGF. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1269-1286.	3.3	28
159	A peptoid antagonist of VEGF Receptor 2 recognizes a "hotspot" in the extracellular domain distinct from the hormone-binding site. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 6338-6343.	3.0	26
160	Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	26
161	Identification of a Monoclonal Antibody That Attenuates Antiphospholipid Syndrome-Related Pregnancy Complications and Thrombosis. <i>PLoS ONE</i> , 2016, 11, e0158757.	2.5	25
162	Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. <i>Gastric Cancer</i> , 2020, 23, 824-836.	5.3	25

#	ARTICLE	IF	CITATIONS
163	The Acellular Fraction of Stored Platelets Promotes Tumor Cell Invasion. Journal of Surgical Research, 2009, 153, 132-137.	1.6	24
164	Clonal Analysis Reveals a Common Progenitor for Endothelial, Myeloid, and Lymphoid Precursors in Umbilical Cord Blood. Circulation Research, 2010, 107, 1460-1469.	4.5	24
165	Autocrine VEGF-VEGF-R loop on podocytes during glomerulonephritis in humans. Nephrology Dialysis Transplantation, 2010, 25, 3170-3180.	0.7	24
166	Epithelialâ€mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib. Carcinogenesis, 2012, 33, 1639-1646.	2.8	24
167	Extracellular Matrix Induction of Intracellular Reactive Oxygen Species. Antioxidants and Redox Signaling, 2017, 27, 774-784.	5.4	24
168	Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- <i>a</i> ]pyrazin-3-ylethynyl)-4-isopropyl- <i>N</i> -(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. Journal of Medicinal Chemistry, 2018, 61, 7977-7990.	6.4	24
169	Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. Frontiers in Oncology, 2019, 9, 1049.	2.8	24
170	Recent advances in understanding cancer-associated fibroblasts in pancreatic cancer. American Journal of Physiology - Cell Physiology, 2020, 319, C233-C243.	4.6	23
171	TIMs, TAMs, and PS- antibody targeting: implications for cancer immunotherapy. Cell Communication and Signaling, 2020, 18, 29.	6.5	23
172	Intravenous delivery of the plasma fraction of stored packed erythrocytes promotes pancreatic cancer growth in immunocompetent mice. Cancer, 2010, 116, 3862-3874.	4.1	22
173	VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment. JCI Insight, 2021, 6, .	5.0	22
174	Does Axl have potential as a therapeutic target in pancreatic cancer?. Expert Opinion on Therapeutic Targets, 2018, 22, 955-966.	3.4	21
175	VEGF and Pleiotrophin Modulate the Immune Profile of Breast Cancer. Cancers, 2010, 2, 970-988.	3.7	20
176	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. Cancer Immunology Research, 2016, 4, 531-540.	3.4	20
177	Loss of Tbk1 kinase activity protects mice from diet-induced metabolic dysfunction. Molecular Metabolism, 2018, 16, 139-149.	6.5	20
178	AXL Is a Driver of Stemness in Normal Mammary Gland and Breast Cancer. IScience, 2020, 23, 101649.	4.1	20
179	Immune Checkpoint Inhibition is Safe and Effective for Liver Cancer Prevention in a Mouse Model of Hepatocellular Carcinoma. Cancer Prevention Research, 2020, 13, 911-922.	1.5	20
180	Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts. Annals of Surgical Oncology, 2016, 23, 583-591.	1.5	18

#	ARTICLE	IF	CITATIONS
181	Perspectives on Hypoxia Signaling in Tumor Stroma. <i>Cancers</i> , 2021, 13, 3070.	3.7	18
182	Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 662-670.	4.1	17
183	Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model. <i>Oncotarget</i> , 2016, 7, 51569-51580.	1.8	17
184	Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. <i>American Journal of Obstetrics and Gynecology</i> , 2009, 200, 180.e1-180.e7.	1.3	16
185	Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6017-6027.	7.0	16
186	AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 1412-1421.	3.4	16
187	Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer. <i>Journal of Cellular Biochemistry</i> , 2003, 90, 492-501.	2.6	14
188	A rapid <i>in vivo</i> screen for pancreatic ductal adenocarcinoma therapeutics. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1201-1211.	2.4	14
189	Cyclooxygenase-2 Inhibition Potentiates the Efficacy of Vascular Endothelial Growth Factor Blockade and Promotes an Immune Stimulatory Microenvironment in Preclinical Models of Pancreatic Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 348-355.	3.4	14
190	CXCL12 in Pancreatic Cancer: Its Function and Potential as a Therapeutic Drug Target. <i>Cancers</i> , 2022, 14, 86.	3.7	14
191	Î”Np63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leaderâ€“Follower Relationship That Drives Collective Invasion. <i>Cancer Research</i> , 2020, 80, 3933-3944.	0.9	13
192	Hemolysis-associated phosphatidylserine exposure promotes polyclonal plasmablast differentiation. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	12
193	Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 493-503.	1.0	12
194	The effect of flow on blood oxygen level dependent ( $R^{*2}$ ) MRI of orthotopic lung tumors. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 3787-3797.	3.0	11
195	Phosphatidylserine (PS) Is Exposed in Choroidal Neovascular Endothelium: PS-Targeting Antibodies Inhibit Choroidal Angiogenesis In Vivo and Ex Vivo. , 2015, 56, 7137.		10
196	Neuropathological Effects of Chemotherapeutic Drugs. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3038-3048.	3.5	10
197	AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 38-47.	4.1	9
198	Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. <i>Clinical and Experimental Metastasis</i> , 2000, 18, 313-319.	3.3	8

#	ARTICLE	IF	CITATIONS
199	The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy. <i>Current Drug Targets</i> , 2016, 17, 1747-1754.	2.1	8
200	Effective Rat Lung Tumor Model for Stereotactic Body Radiation Therapy. <i>Radiation Research</i> , 2016, 185, 616-622.	1.5	7
201	&lt;p&gt;APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice&lt;/p&gt;. <i>Breast Cancer: Targets and Therapy</i> , 2019, Volume 11, 249-259.	1.8	7
202	High-dimensional immunotyping of tumors grown in obese and non-obese mice. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	7
203	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 3183-3183.	8.2	7
204	Î²1 Syntrophin Supports Autophagy Initiation and Protects against Cerulein-Induced Acute Pancreatitis. <i>American Journal of Pathology</i> , 2019, 189, 813-825.	3.8	6
205	Faulty ECM Signaling Facilitates Autoimmune Lymphomagenesis. <i>Cancer Discovery</i> , 2014, 4, 25-26.	9.4	5
206	Stromal TGFÎ²R2 signaling: a gateway to progression for pancreatic cancer. <i>Molecular and Cellular Oncology</i> , 2015, 2, e975606.	0.7	5
207	Woodchuck VEGF (wVEGF) characteristics: Model for angiogenesis and human hepatocellular carcinoma directed therapies. <i>Archives of Biochemistry and Biophysics</i> , 2019, 661, 97-106.	3.0	5
208	Loss of BAP1 Leads to More YAPing in Pancreatic Cancer. <i>Cancer Research</i> , 2020, 80, 1624-1625.	0.9	5
209	Co-localization of prothrombin fragment F1+2 and VEGF-R2-bound VEGF in human colon cancer. <i>Anticancer Research</i> , 2011, 31, 843-7.	1.1	5
210	Targeting TAM to Tame Pancreatic Cancer. <i>Targeted Oncology</i> , 2020, 15, 579-588.	3.6	4
211	Anti-VEGF Therapy Revived by c-Met Inhibition, but Is c-Met the Answer?. <i>Cancer Discovery</i> , 2012, 2, 211-213.	9.4	3
212	Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics. <i>Scientific Reports</i> , 2020, 10, 20662.	3.3	3
213	Mesothelial Cell-Derived Antigen-Presenting Cancer-Associated Fibroblasts Induce Expansion of Regulatory T Cells in Pancreatic Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
214	Beyond Stiffness. <i>American Journal of Pathology</i> , 2020, 190, 1622-1624.	3.8	3
215	Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.. <i>Clinical Cancer Research</i> , 2014, 20, B30-B30.	7.0	3
216	Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9081-9081.	1.6	3

#	ARTICLE	IF	CITATIONS
217	Collagen Signaling in Cancer. , 2019, , 89-108.		2
218	Procoagulant activities of skeletal muscle and cardiac myosins require both myosin protein and myosin-associated anionic phospholipids. Blood, 2021, 137, 1839-1842.	1.4	2
219	Targeting Inside-Out Phospholipids on Tumor Blood Vessels in Pancreatic Cancer. , 2006, , 179-194.		1
220	147. The Acellular Fraction of Stored Platelets Promotes Cancer Invasion. Journal of Surgical Research, 2008, 144, 241-242.	1.6	1
221	Update on vascular disrupting agents for cancer therapy. Therapy: Open Access in Clinical Medicine, 2011, 8, 403-413.	0.2	1
222	Phosphatidylserine-Targeting Monoclonal Antibodies Exhibit Distinct Biochemical and Cellular Effects on Anti-CD3/CD28- Stimulated T Cell IFN- $\gamma$ and TNF- $\alpha$ Production. Journal of Immunology, 2021, 207, 436-448.	0.8	1
223	Drivers of EMT and Immune Evasion. , 2017, , 221-239.		1
224	Mouse Models of Pancreatic Cancer. , 2013, , 57-91.		1
225	Abstract A04: TBK1 as a novel mediator of K-Ras driven pancreatic cancer. , 2014, , .		1
226	Are TEMs Canceled? Questioning the Functional Relevance of Tie2-Expressing Macrophages. Cancer Research, 2022, 82, 1172-1173.	0.9	1
227	The Extracellular Matrix of Tumors: A Focus on Fibronectin and Fibulin-5. Biology of Extracellular Matrix, 2017, , 1-15.	0.3	0
228	Location matters: Profiling diffuse type gastric cancer at the single cell level. Clinical Cancer Research, 2021, 27, clincanres.2935.2021.	7.0	0
229	The Function of SPARC in Tumor Cell Biology: SPARC as a Modulator of Cell-Extracellular Matrix Interaction. , 2010, , 171-189.		0
230	SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF- $\beta$ 1 activity. Journal of Experimental Medicine, 2011, 208, i22-i22.	8.5	0
231	Effect of 2G8, a TGF- $\beta$ 2 inhibitor, on TGF- $\beta$ signaling and migration in an immunocompetent pancreatic cancer model.. Journal of Clinical Oncology, 2012, 30, 230-230.	1.6	0
232	Use of PG545, a heparanase inhibitor, to inhibit pancreatic cancer tumor cell proliferation and migration in vitro and in vivo.. Journal of Clinical Oncology, 2012, 30, 234-234.	1.6	0
233	Rgs16 is a pancreatic reporter of chronic hyperglycemia in diabetes. FASEB Journal, 2012, 26, 759.6.	0.5	0
234	Ligand induced activation of VEGFR during angiogenesis. FASEB Journal, 2012, 26, 971.2.	0.5	0

#	ARTICLE	IF	CITATIONS
235	Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model.. Journal of Clinical Oncology, 2012, 30, e13563-e13563.	1.6	0
236	Abstract B19: Rapid in vivo screen of pancreatic ductal adenocarcinoma therapeutics. , 2014, , .		0
237	919â€¦Tegavivint reduces the immunosuppressive macrophage phenotype in a preclinical co-culture model of the non-small cell lung cancer tumor microenvironment. , 2021, 9, A964-A964.		0
238	Procoagulant Activity of Skeletal Muscle Myosin Is Not Caused By Contaminating Phosphatidylserine-Vesicles. Blood, 2020, 136, 20-21.	1.4	0